What Angiotensin II is
Angiotensin II is a core vasoactive peptide in renin-angiotensin-aldosterone system signaling and blood-pressure regulation.
Angiotensin II is grouped under Endogenous / Biology on PeptideFactCheck because it belongs in the index because it is one of the central peptides in cardiovascular physiology.
The useful starting point is to separate the molecule itself from the internet story around it. It belongs in the index because it is one of the central peptides in cardiovascular physiology.
Why people keep looking it up
It belongs in the index because it is one of the central peptides in cardiovascular physiology.
Angiotensin II is a core vasoactive peptide in renin-angiotensin-aldosterone system signaling and blood-pressure regulation.
Angiotensin II tends to stay in the conversation because it touches a familiar public theme: vasoactive peptide, blood pressure, and raas signaling. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
High-confidence endocrine and cardiovascular peptide biology.
Human physiology is well established.
Mechanistic support across vascular and renal biology is extensive.
Why this page carries the current tier: High-confidence endocrine and cardiovascular peptide biology.
The current seed trail for Angiotensin II is pulling from 2 databases sources and 1 literature source.
Safety, limits, and regulatory context
This is a foundational physiology entry rather than a self-experiment peptide category.
Angiotensin II is tracked here as endogenous biology, distinct from specific drug products.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Angiotensin II. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Angiotensin II is CID 172198. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 172198
- Formula
- C50H71N13O12
- Molecular weight
- 1046.2
- InChIKey
- CZGUSIXMZVURDU-JZXHSEFVSA-N
Matched synonyms include ANGIOTENSIN II, 4474-91-3, Human angiotensin II, Angiotensin II (human), Ang II, 5-L-Isoleucineangiotensin II, 5-Isoleucine-angiotensin II, Angiotensin II (mouse).
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Angiotensin II returns 348 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Angiotensin II returns 75635 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- ANGIOTENSIN II
- Generic names
- ANGIOTENSIN II
- Routes
- INTRAVENOUS
- Application numbers
- ANDA216966
Indications and usage. 1 INDICATIONS AND USAGE Angiotensin II Injection increases blood pressure in adults with septic or other distributive shock. Angiotensin II Injection is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. (1)
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS • There is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive Angiotensin II. Use concurrent venous thromboembolism (VTE) prophylaxis. ( 5.1 , 6.1 ) 5.1 Risk for Thrombosis The safety of Angiotensin II was evaluated in 321 adults with septic or other distributive shock in a randomized, double-blind, placebo-controlled study, ATHOS-3. There was...
Contraindications. 4 CONTRAINDICATIONS None. None (4.1)
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.